These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
ETFMG on Thursday launched a new ETF that offers people a way to invest in cannabis companies that do at least half their business in the United States.
Canadian marijuana grower Tilray is getting a big boost Friday, a result of a stock upgrade and price target lift from analysts at Jefferies.
Frequency Therapeutics shares were absolutely crushed on Tuesday but saw a bit of a recovery early Wednesday.
Amazon on Wednesday announced an expansion of its health care service to all employers in Washington state. The announcement took a bite out of some competing health care stocks.
Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.
BofA Securities feels these four top medtech companies are all poised for potential positive news and developments in the near future. These stocks could be good additions to growth portfolios...
Johnson & Johnson officially enters the fight against COVID-19 as its single-shot vaccine was approved over the weekend. It plans to deliver 100 million single-shot vaccines during the first half of...
An increasing number of people are surviving within five years of being diagnosed with almost all major types of cancer.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Many rural hospitals have little or no financial reserves and have posted financial losses that have gone on for a long time.
Gritstone pushed higher on Tuesday after the company reported that it was advancing the development of a second-generation vaccine against SARS-CoV-2.
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.